Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.67 USD
-0.15 (-3.93%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.68 +0.01 (0.27%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Atea Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -135.96 | -115.91 | 121.19 | -10.95 | -14.03 |
Depreciation/Amortization & Depletion | -15.03 | -5.21 | 0.03 | 0.02 | 0.02 |
Net Change from Assets/Liabilities | 16.16 | -46.59 | -247.85 | 300.21 | 0.56 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 49.43 | 46.72 | 39.62 | 7.46 | 0.62 |
Net Cash From Operating Activities | -85.40 | -120.98 | -87.01 | 296.73 | -12.83 |
Property & Equipment | 0.00 | -1.94 | 0.00 | -0.03 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 40.30 | -453.47 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 40.30 | -455.41 | 0.00 | -0.03 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.26 | 0.37 | 1.47 | 531.75 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.26 | 0.37 | 1.47 | 531.75 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -44.84 | -576.02 | -85.54 | 828.46 | -12.83 |
Cash at Beginning of Period | 188.66 | 764.68 | 850.22 | 21.77 | 34.60 |
Cash at End of Period | 143.82 | 188.66 | 764.68 | 850.22 | 21.77 |
Diluted Net EPS | -1.63 | -1.39 | 1.37 | -0.51 | NA |
Fiscal Year End for Atea Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -103.69 | -63.17 | -135.96 | -96.79 | -63.65 |
Depreciation/Amortization & Depletion | -6.30 | -3.38 | -15.03 | -10.79 | -6.58 |
Net Change from Assets/Liabilities | 2.62 | 14.10 | 16.16 | 6.75 | -0.63 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 25.31 | 12.59 | 49.43 | 37.27 | 24.89 |
Net Cash From Operating Activities | -82.07 | -39.87 | -85.40 | -63.56 | -45.97 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 181.49 | 56.80 | 40.30 | 12.53 | 71.05 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 181.49 | 56.80 | 40.30 | 12.53 | 71.05 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.15 | 0.15 | 0.26 | 0.26 | 0.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.15 | 0.15 | 0.26 | 0.26 | 0.17 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 99.57 | 17.09 | -44.84 | -50.77 | 25.24 |
Cash at Beginning of Period | 143.82 | 143.82 | 188.66 | 188.66 | 188.66 |
Cash at End of Period | 243.39 | 160.91 | 143.82 | 137.89 | 213.90 |
Diluted Net EPS | -0.48 | -0.75 | -0.46 | -0.40 | -0.34 |